• Santen Pharmaceutical Co., Ltd.
    Comprehensive Ophthalmology

    Santen Pharmaceutical Co., Ltd. announced that Japan's Ministry of Health, Labor and Welfare has approved Alesion 0.05% Ophthalmic Solution (generic name: epinastine HCl) for treating allergic conjunctivitis.

    Japanese clinical trials showed that epinastine HCl, the active ingredient in Alesion 0.05% Ophthalmic Solution, blocks histamine H1 receptors and inhibits the release of chemical mediators from mast cells, alleviating ocular itching and hyperemia. No ocular or systemic serious adverse drug reactions were observed in these studies.